Bumper Offer - Urjas oil Just @ Rs. 1
Dubataran 75 Capsule is a commercial drug that is prescribed in the form of Capsule. It is primarily used for the treatment of Bleeding. Secondary and off-label uses of Dubataran 75 Capsule have also been mentioned below.
The optimal dosage of Dubataran 75 Capsule is largely dependent on the individual's body weight, medical history, gender and age. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. For detailed information on this, read through the dosage section.
While these are the most often observed Dubataran 75 Capsule side effects, there are can be others also. These have been listed below. Usually, these side effects of Dubataran 75 Capsule go away soon, and do not persist beyond the duration of the treatment. However, if these continue for a longer time, consult your doctor right away.
It is also important to note that Dubataran 75 Capsule has a Moderate effect for pregnant women and Safe effect on lactating mothers. Warnings related to Dubataran 75 Capsule's effects on the liver, heart and kidney, if any, have been listed below.
Dubataran 75 Capsule can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Dubataran 75 Capsule in conditions like Blood Cancer, Colour Blindness, Allergy.
Drug reaction of Dubataran 75 Capsule with other medicines has been reported. See below for a complete list.
You should also be aware that Dubataran 75 Capsule is safe while driving, and is addiction.
Dubataran 75 Capsule is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
| Adult(Female) |
|
| 13 - 18 years (Adolescent) |
|
Based on research, the following side effects have been observed when Dubataran 75 Capsule is used -
Severe
Moderate
Mild
Is the use of Dubataran 75 Capsule safe for pregnant women?
Dubatran can have harmful effects in pregnant women. If you experience any discomfort after using Dubatran, then discontinue the use and take your doctor's advice.
Is the use of Dubataran 75 Capsule safe during breastfeeding?
Dubatran is completely safe for breastfeeding women.
What is the effect of Dubataran 75 Capsule on the Kidneys?
There may be some adverse effects on kidney after taking Dubatran. If you observe any such side effects, stop taking this drug. Consume this medicine again only if your doctor advises you to do so.
What is the effect of Dubataran 75 Capsule on the Liver?
Very few cases of side effects of Dubatran on the liver have been reported.
What is the effect of Dubataran 75 Capsule on the Heart?
You may experience side effects on your heart after taking Dubatran. If this happens, then discontinue its use. Consult your medical practitioner, and do as he/she suggests.
Dubataran 75 Capsule should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Dubataran 75 Capsule unless your doctor advises you to do so -
Is this Dubataran 75 Capsule habit forming or addictive?
Dubataran 75 Capsule is not addictive in nature.
Is it safe to drive or operate heavy machinery when consuming?
Dubataran 75 Capsule does not cause dizziness or sleep, so you can drive a vehicle or operate machinery also.
Is it safe?
Yes, but consume Dubataran 75 Capsule only on doctor's advice.
Is it able to treat mental disorders?
There is no benefit of taking Dubataran 75 Capsule for mental disorders.
Interaction between Food and Dubataran 75 Capsule
There isn't any research available on the side effects of taking Dubataran 75 Capsule with food.
Interaction between Alcohol and Dubataran 75 Capsule
No research has been done on this till date. Therefore, it is not known what the effect of taking Dubataran 75 Capsule with alcohol will be.
Dubatran is available in the form of an injection and tablet. Injection must be taken under the supervision of a doctor. The tablet should be taken orally or by mouth. Depending upon your condition, your doctor will suggest you a dosing schedule. It is important that you stick to this schedule. It can be taken with or without food. It should be taken at exactly the same time every day so that you don't miss the dose. If your bleeding doesn't reduce or gets worse, call your doctor immediately.
Yes, Dubatran may cause allergy in rare cases. The symptoms could be rash, itching, extreme dizziness, swelling of the tongue, throat, and face, difficulty in breathing, etc. If you experience any of these symptoms, discontinue using Dubatran and talk to your doctor immediately.
Dubatran is the brand name for tranexamic acid. It belongs to class drugs known as antifibrinolytics. It is available in the form of injection and tablets. It is used to prevent or reduce hemorrhage in patients struggling with hemophilia, to lessen the need for a replacement therapy during and after a tooth extraction procedure, and for managing excessive bleeding during surgery, trauma and menstruation.
No, Dubatran is not a steroid. It is an anti-fibrinolytic agent that stops the process of fibrinolysis, preventing blood loss.
No, Dubatran doesn't cause anxiety. Anxiety is a group of mental disorder characterized by excessive fear and feels nervousness. It has not been reported by the patients who are taking it. However, if you experience anxiety after taking this drug then it might be due to some other medical condition. You are advised to discuss it with your doctor.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 628-629
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lysteda™ (tranexamic acid)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Cyklokapron® (tranexamic acid)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 628-629
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lysteda™ (tranexamic acid)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Cyklokapron® (tranexamic acid)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 628-629
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lysteda™ (tranexamic acid)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Cyklokapron® (tranexamic acid)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 628-629
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lysteda™ (tranexamic acid)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Cyklokapron® (tranexamic acid)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 628-629
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lysteda™ (tranexamic acid)
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Cyklokapron® (tranexamic acid)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 385
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 623-624
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Pradaxa® (dabigatran etexilate mesylate)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 385
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 623-624